MorphoSys AG
XETRA:MOR
MorphoSys AG
Revenue
MorphoSys AG
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
MorphoSys AG
XETRA:MOR
|
Revenue
€238.3m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
26%
|
CAGR 10-Years
12%
|
|
BioNTech SE
NASDAQ:BNTX
|
Revenue
€3.8B
|
CAGR 3-Years
99%
|
CAGR 5-Years
97%
|
CAGR 10-Years
N/A
|
|
CureVac NV
NASDAQ:CVAC
|
Revenue
€53.8m
|
CAGR 3-Years
3%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
Immatics NV
NASDAQ:IMTX
|
Revenue
€54m
|
CAGR 3-Years
20%
|
CAGR 5-Years
70%
|
CAGR 10-Years
N/A
|
|
Biotest AG
XETRA:BIO
|
Revenue
€684.6m
|
CAGR 3-Years
12%
|
CAGR 5-Years
11%
|
CAGR 10-Years
3%
|
|
Formycon AG
XETRA:FYB
|
Revenue
€42.5m
|
CAGR 3-Years
8%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
See Also
What is MorphoSys AG's Revenue?
Revenue
238.3m
EUR
Based on the financial report for Dec 31, 2023, MorphoSys AG's Revenue amounts to 238.3m EUR.
What is MorphoSys AG's Revenue growth rate?
Revenue CAGR 10Y
12%
Over the last year, the Revenue growth was -14%. The average annual Revenue growth rates for MorphoSys AG have been -10% over the past three years , 26% over the past five years , and 12% over the past ten years .